Screener
Regenxbio RGNX Cost Of License And Royalty Revenues
Cost Of License And Royalty Revenues at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:CostOfLicenseAndRoyaltyRevenues.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Service revenue | 4,178 | 2,894 | 5,481 | 4,857 |
| Total revenues | 108,019 | 21,359 | 114,412 | 110,371 |
| Operating Expenses | ||||
| Cost of license and royalty revenues | 1,042 | 5,209 | 12,116 | 8,645 |
| Research and development | 56,086 | 59,500 | 113,425 | 112,587 |
| General and administrative | 21,616 | 19,883 | 42,922 | 40,230 |
| Other operating expenses | 12 | 45 | 48 | 60 |
| Total operating expenses | 78,756 | 84,637 | 168,511 | 161,522 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's cost of license and royalty revenues?
- Regenxbio (RGNX) reported cost of license and royalty revenues of $1.04M in Q2 2026.
- How has Regenxbio's cost of license and royalty revenues changed year-over-year?
- Regenxbio's cost of license and royalty revenues decreased by 80.0% year-over-year, from $5.21M to $1.04M.
- What does cost of license and royalty revenues mean?
- Cost Of License And Royalty Revenues as reported by REGENXBIO Inc..
Ask your AI about Regenxbio's cost of license and royalty revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude